J
James M. Provenzale
Researcher at Duke University
Publications - 337
Citations - 24249
James M. Provenzale is an academic researcher from Duke University. The author has contributed to research in topics: Diffusion MRI & Fractional anisotropy. The author has an hindex of 86, co-authored 334 publications receiving 22963 citations. Previous affiliations of James M. Provenzale include Johns Hopkins University & Veterans Health Administration.
Papers
More filters
Journal ArticleDOI
Lymphomas and High-Grade Astrocytomas: Comparison of Water Diffusibility and Histologic Characteristics
TL;DR: Measurements of water diffusivity and cellularity suggest that higher cellularity contributes to more restricted diffusion within lymphomas and high-grade astrocytomas.
Journal ArticleDOI
Magnetic resonance imaging and head circumference study of brain size in autism: birth through age 2 years.
Heather C. Hazlett,Michele D. Poe,Guido Gerig,Rachel Gimpel Smith,James M. Provenzale,Allison Kinder Ross,John H. Gilmore,Joseph Piven +7 more
TL;DR: Generalized enlargement of gray and white matter cerebral volumes, but not cerebellar volumes, are present at 2 years of age in autism, and indirect evidence suggests that this increased rate of brain growth in autism may have its onset postnatally in the latter part of the first year of life.
Journal ArticleDOI
Transplantation of Umbilical-Cord Blood in Babies with Infantile Krabbe's Disease
Maria L. Escolar,Michele D. Poe,James M. Provenzale,Karen C. Richards,June Allison,Susan Wood,David A. Wenger,Daniel Pietryga,Donna A. Wall,Martin A. Champagne,Richard P. Morse,William Krivit,Joanne Kurtzberg +12 more
TL;DR: Infants who underwent transplantation before the development of symptoms showed progressive central myelination and continued gains in developmental skills, and most had age-appropriate cognitive function and receptive language skills, but a few had mild- to-moderate delays in expressive language and mild-to-severe delays in gross motor function.
Journal ArticleDOI
Effect of a Novel Free Radical Scavenger, Edaravone (MCI-186), on Acute Brain Infarction
Wolfgang Müllges,Dorothea Franke,Wilko Reents,Jörg Babin-Ebell,Klaus V. Toyka,N.U. Ko,S.C. Johnston,W.L. Young,V. Singh,A.L. Klatsky,Filipa Falcão,Norbert G. Campeau,Eelco F. M. Wijdicks,John D. Atkinson,Jimmy R. Fulgham,Raymond Tak Fai Cheung,Pui W. Cheng,Wai M. Lui,Gilberto K.T. Leung,Ting-Yim Lee,Stefan T. Engelter,James M. Provenzale,Jeffrey R. Petrella,David M. DeLong,Mark J. Alberts,Stefan Evers,Darius G. Nabavi,Alexandra Rahmann,Christoph Heese,Doris Reichelt,Ingo-W. Husstedt,Antonio Arauz,Leora Velásquez,Carlos Cantú,Juan A. Nader,Mario López,Luis Murillo,Yolanda Aburto,Patrizia Nencini,Cristina Sarti,Rinaldo Innocenti,Giovanni Pracucci,Domenico Inzitari,Kyoung Heo,Sun Ah Park,Jong Yun Lee,Byung In Lee,Seung-Koo Lee,Patricia Canhão,José M. Ferro,Dénes Páll,Georgios Settakis,Éva Katona,László Csiba,György Kakuk,Martien Limburg,Dániel Bereczki,Béla Fülesdi,Maurizio Paciaroni,Valeria Caso,Gabriela Cardaioli,Francesco Corea,Paolo Milia,Michele Venti,Mohammed Hamam,Gian Piero Pelliccioli,Lucilla Parnetti,Virgilio Gallai,Thanh G. Phan,John Huston +69 more
TL;DR: Edaravone represents a neuroprotective agent which is potentially useful for treating acute ischemic stroke, since it can exert significant effects on functional outcome as compared with placebo.
Journal ArticleDOI
DNA mismatch repair and O6-alkylguanine-DNA alkyltransferase analysis and response to Temodal in newly diagnosed malignant glioma.
Henry S. Friedman,Roger E. McLendon,Tracy Kerby,M Dugan,Sandra H. Bigner,AJ Henry,David M. Ashley,J Krischer,Shelley Lovell,Karima Rasheed,F Marchev,AJ Seman,Ilkcan Cokgor,Jeremy N. Rich,Elizabeth S. Stewart,Colvin Om,James M. Provenzale,Darell D. Bigner,Michael M. Haglund,Allan H. Friedman,Paul Modrich +20 more
TL;DR: Temodal has activity against newly diagnosed GBM and AA and warrants continued evaluation of this agent, and pretherapy analysis of tumor DNA mismatch repair and, particularly, AGT protein expression may identify patients in whom tumors are resistant to Temodal.